Fig. 6From: Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseasesDistribution of FDA orphan drug designations with at least one approval within broad disease category, 1983—2019Back to article page